Belarus’ pharmaceutical industry is gathering momentum
Mr Usanov, can the pharmaceutical industry become one of the major revenueearners in our country?
Like many other countries, Belarus attaches utmost importance to this industry. Pharmaceutics and biotechnologies have recently become the fastest growing industries in the developed and developing countries demonstrating a 10% growth per year. In 2010 alone, the total sales of pharmaceutical products on the major global pharmaceutical markets made $656.5 billion.
Belarus’ pharmaceutical industry is on the threshold of remarkable transformations. Five years from now, it will grow into one of the most innovation-intensive domestic industries. The Belarusian pharmaceutical industry will, in fact, get a new face which will be well-recognized not only in the country, but throughout the world. Belarus is going to sell more domestic drugs and vitamins, which quality will rival imported ones. Director General of the Chemical Synthesis and Biotechnologies Research Center, chief of the Institute of Bioorganic Chemistry, member of the National Academy of Sciences of Belarus, Professor Sergei USANOV tells the Economy of Belarus Magazine about the new development strategy and new image of the industry, new technologies and investment projects.
The figure is not so impressive in Belarus. For example, in 2010 the domestic market was estimated at $676.5 million in selling prices, up by 9.9% in money terms and up by 1.2% in physical terms. In January-august 2011, the Belarusian pharmaceutical market expanded by 5.6% in money terms and by 6.8% in physical terms. Over 6,000 drugs and pharmaceutical substances have been registered in Belarus, of which 950 names are produced by domestic companies.
This is naturally not enough to advance to the leading positions. At present, Belarus-made pharmaceutical substances account for 26% of the drug production technologies, while the imported substances are worth dozens of millions of dollars. The country still heavily relies on pharmaceutical imports.
This issue is to be addressed by the pharmaceutics and biotechnologies development concept for 20112015 and for the period until 2020. Its major objective is to reduce the reliance on drug imports by increasing the share of domestic drugs in total consumption up to 50% in money terms.
In line with the instructions of the head of state, by 2015 Belarusian companies should increase the pharmaceutical production three times compared with 2010. The export of medicines should rise by not less than 3.7-4 times, including by means of GMP certification of the existing production.
In line with the government program “Import substituting pharmaceutical products”, Belarus is set to establish 12 new production facilities to make import substituting pharmaceutical substances and finished pharmaceutical and diagnostic products, including 32 pharmaceutical substances and 110 drugs, including 53 original ones. What reforms will be implemented in the domestic pharmaceutical industry?
Reforms are already underway. The head of state passed Decree
The share of Belarus-made medicines should reach 50% on the domestic market